Published in Mediators Inflamm on April 17, 2013
Vitamin D, Insulin Resistance and Inflammation in ESRD | NCT00656032
Vitamin D Replacement in Statin-Induced Myopathy | NCT01400009
Vitamin D Repletion in Coronary Artery Disease | NCT01570309
Silymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling. J Nat Prod (2015) 0.83
Update in vitamin D and multiple sclerosis. Neurosciences (Riyadh) (2015) 0.81
Vitamin D receptor agonists: suitable candidates as novel therapeutic options in autoimmune inflammatory myopathy. Biomed Res Int (2014) 0.80
Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse. Arthritis Res Ther (2014) 0.79
Mycobacterial infection induces a specific human innate immune response. Sci Rep (2015) 0.79
The vitamin D receptor agonist BXL-01-0029 as a potential new pharmacological tool for the treatment of inflammatory myopathies. PLoS One (2013) 0.78
Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. J Endocrinol Invest (2015) 0.76
CXCL10/IP-10 Neutralization Can Ameliorate Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Rats. PLoS One (2017) 0.75
PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach. Oncotarget (2016) 0.75
No evidence for an association of vitamin D deficiency and migraine: a systematic review of the literature. Biomed Res Int (2014) 0.75
Testosterone insulin-like effects: an in vitro study on the short-term metabolic effects of testosterone in human skeletal muscle cells. J Endocrinol Invest (2017) 0.75
Profiling of selenium absorption and accumulation in healthy subjects after prolonged L-selenomethionine supplementation. J Endocrinol Invest (2017) 0.75
Sport and male sexuality. J Endocrinol Invest (2017) 0.75
The steroid and thyroid hormone receptor superfamily. Science (1988) 25.68
NF-kappaB regulation in the immune system. Nat Rev Immunol (2002) 15.80
The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest (1998) 6.51
Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med (1996) 6.36
Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol (2008) 5.37
1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science (1983) 4.34
Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med (1987) 4.21
Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A (1981) 4.12
Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med (2000) 3.84
1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol (2000) 3.82
Vitamin D and diabetes. Diabetologia (2005) 3.58
Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol (2007) 3.49
Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol (2005) 3.44
Vitamin D: its role and uses in immunology. FASEB J (2001) 3.40
The role of the vitamin D endocrine system in health and disease. N Engl J Med (1989) 3.37
Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest (1999) 3.21
Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr (2003) 3.04
An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med (2003) 2.91
Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol (2001) 2.75
Structure-function relationships in the vitamin D endocrine system. Endocr Rev (1995) 2.54
Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol (2006) 2.51
The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med (2002) 2.45
Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest (1984) 2.43
1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest (1984) 2.39
A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes (2002) 2.24
1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol (2009) 2.22
Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med (2001) 2.17
Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 2.14
1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr (1998) 2.06
gamma-Interferon stimulates production of 1,25-dihydroxyvitamin D3 by normal human macrophages. Biochem Biophys Res Commun (1985) 1.97
Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol (2003) 1.97
Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol (1995) 1.90
1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci U S A (1987) 1.89
Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia (2006) 1.87
Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood (2005) 1.83
1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol (1985) 1.79
Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int (2009) 1.78
Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol (1998) 1.78
Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol (2007) 1.74
Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol (2001) 1.63
25-Hydroxyvitamin D3 metabolism by lipopolysaccharide-stimulated normal human macrophages. J Clin Endocrinol Metab (1987) 1.54
Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood (2003) 1.47
Vitamin D3: a helpful immuno-modulator. Immunology (2011) 1.46
A vitamin D analog down-regulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol (2004) 1.43
Role of chemokines in endocrine autoimmune diseases. Endocr Rev (2007) 1.43
Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation (2001) 1.42
Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis (2001) 1.42
Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol (1998) 1.39
The vitamin D receptor: new paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D(3). Endocrinol Metab Clin North Am (2010) 1.39
Ligation of TLR9 induced on human IL-10-secreting Tregs by 1alpha,25-dihydroxyvitamin D3 abrogates regulatory function. J Clin Invest (2009) 1.35
1,25(OH)2-vitamin D3 induces translocation of the vitamin D receptor (VDR) to the plasma membrane in skeletal muscle cells. J Cell Biochem (2002) 1.32
Serum levels of ifn-inducible PROTEIN-10 relating to the activity of systemic lupus erythematosus. Cytokine (2000) 1.29
Expansion of antigen-specific regulatory T cells with the topical vitamin d analog calcipotriol. J Immunol (2009) 1.26
Identification of a specific binding protein for 1 alpha,25-dihydroxyvitamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem (1994) 1.26
1 alpha,25-dihydroxyvitamin D3 promotes fusion of mouse alveolar macrophages both by a direct mechanism and by a spleen cell-mediated indirect mechanism. Proc Natl Acad Sci U S A (1983) 1.24
Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev (2011) 1.24
Investigation of hypercalcemia. Clin Biochem (2012) 1.23
Vitamin D and colon cancer. Endocr Relat Cancer (2012) 1.20
Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol (2005) 1.20
Vitamin D nutritional policy needs a vision for the future. Exp Biol Med (Maywood) (2010) 1.19
Human T lymphocytes are direct targets of 1,25-dihydroxyvitamin D3 in the immune system. J Steroid Biochem Mol Biol (2010) 1.18
Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells. Endocrinology (2008) 1.18
Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. J Immunol (2006) 1.16
Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford) (2010) 1.13
A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther (2003) 1.11
Identification and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol (2000) 1.10
Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol (2001) 1.10
Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol (2003) 1.09
1,25-Dihydroxyvitamin D3 enhances the generation of nonspecific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR. Cell Immunol (1992) 1.07
CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. Am J Physiol Lung Cell Mol Physiol (2005) 1.06
CXCL10: a candidate biomarker in transplantation. Clin Chim Acta (2012) 1.06
Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology (1995) 1.06
Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation (2003) 1.04
Allergic humans are hyporesponsive to a CXCR3 ligand-mediated Th1 immunity-promoting loop. FASEB J (2003) 1.04
Transpleural gradient of 1,25-dihydroxyvitamin D in tuberculous pleuritis. J Clin Invest (1989) 1.01
Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev (2011) 1.00
1,25(OH)2D2 production by T lymphocytes and alveolar macrophages recovered by lavage from normocalcemic patients with tuberculosis. J Clin Invest (1990) 1.00
A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Clin Exp Immunol (1998) 0.98
Prevention of type I diabetes in nonobese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D3 in combination with a short induction course of cyclosporin A. Endocrinology (1998) 0.97
Vitamin D receptor agonists: opportunities and challenges in drug discovery. Curr Top Med Chem (2006) 0.97
Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. J Neuroimmunol (2008) 0.97
Vitamin D and breast cancer. Oncologist (2012) 0.96
Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J Dermatol Sci (2004) 0.96
The regulatory effects of all-trans-retinoic acid on isotype switching: retinoic acid induces IgA switch rearrangement in cooperation with IL-5 and inhibits IgG1 switching. Cell Immunol (1999) 0.94
Primary and secondary prevention of Type 1 diabetes. Diabet Med (2013) 0.94
Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. Eur J Cell Biol (2011) 0.94
Inhibition of acute and chronic allograft rejection in mouse models by BXL-628, a nonhypercalcemic vitamin D receptor agonist. Transplantation (2005) 0.93
1,25-Dihydroxyvitamin D3 prolongs graft survival without compromising host resistance to infection or bone mineral density. Transplantation (1998) 0.92
Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation (2000) 0.91
Novel insights in the immune function of the vitamin D system: synergism with interferon-beta. J Steroid Biochem Mol Biol (2006) 0.91
Donor T cell activation initiates small bowel allograft rejection through an IFN-gamma-inducible protein-10-dependent mechanism. J Immunol (2002) 0.91
Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J Endocrinol (2007) 0.90
Impaired bone marrow-derived macrophage differentiation in vitamin D deficiency. Cell Immunol (1993) 0.90
Comparison of the effects of 1,25-dihydroxyvitamin D3 on T lymphocyte subpopulations. Eur J Immunol (1987) 0.90
Prolongation of allograft survival by 1,25-dihydroxyvitamin D3. Transplantation (1998) 0.90
Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin Exp Immunol (2009) 0.90
Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J Clin Endocrinol Metab (2005) 0.89
1 alpha,25-Dihydroxyvitamin D3 (calcitriol) stimulates proliferation of human circulating monocytes in vitro. FEBS Lett (1985) 0.87
The fate of bone after renal transplantation. J Nephrol (2004) 0.87
1 alpha,25-Dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts. Hepatology (2001) 0.86
Regenerative potential of embryonic renal multipotent progenitors in acute renal failure. J Am Soc Nephrol (2007) 2.42
Prevalence of abnormal electrocardiograms in a large, unselected population undergoing pre-participation cardiovascular screening. Eur Heart J (2007) 2.04
Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol (2009) 1.32
Role of the ductal transcription factors HNF6 and Sox9 in pancreatic acinar-to-ductal metaplasia. Gut (2012) 1.14
Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation. Exp Neurol (2009) 1.10
CXCL10: a candidate biomarker in transplantation. Clin Chim Acta (2012) 1.06
Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the rat. J Sex Med (2006) 1.05
Expression and function of gonadotropin-releasing hormone (GnRH) receptor in human olfactory GnRH-secreting neurons: an autocrine GnRH loop underlies neuronal migration. J Biol Chem (2003) 0.99
Negative association between trunk fat, insulin resistance and skeleton in obese women. World J Diabetes (2013) 0.98
Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: implication for assessment of disease activity and treatment. J Neuroimmunol (2008) 0.97
Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male (2012) 0.96
ERK5/MAPK is activated by TGFbeta in hepatocytes and required for the GSK-3beta-mediated Snail protein stabilization. Cell Signal (2008) 0.96
Inflammatory response in human skeletal muscle cells: CXCL10 as a potential therapeutic target. Eur J Cell Biol (2011) 0.94
BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate (2007) 0.90
Elevated serum interferon-gamma-inducible chemokine-10/CXC chemokine ligand-10 in autoimmune primary adrenal insufficiency and in vitro expression in human adrenal cells primary cultures after stimulation with proinflammatory cytokines. J Clin Endocrinol Metab (2005) 0.89
Expression of the novel adrenocorticotropin-responsive gene selective Alzheimer's disease indicator-1 in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. J Clin Endocrinol Metab (2004) 0.89
Oxytocin mediates the estrogen-dependent contractile activity of endothelin-1 in human and rabbit epididymis. Endocrinology (2005) 0.86
Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine (2010) 0.83
Acute exercise modulates BDNF and pro-BDNF protein content in immune cells. Med Sci Sports Exerc (2012) 0.82
Development of human striatal anlagen after transplantation in a patient with Huntington's disease. Exp Neurol (2008) 0.82
Skeletal alterations in women affected by obesity. Aging Clin Exp Res (2013) 0.81
Tadalafil alters energy metabolism in C2C12 skeletal muscle cells. Acta Biochim Pol (2011) 0.81
Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. J Sex Med (2010) 0.80
Comparison between VDR analogs and current immunosuppressive drugs in relation to CXCL10 secretion by human renal tubular cells. Transpl Int (2010) 0.80
Growth hormone abuse: methods of detection. Trends Endocrinol Metab (2005) 0.80
The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol (2006) 0.80
Effects of tadalafil administration on plasma markers of exercise-induced muscle damage, IL6 and antioxidant status capacity. Eur J Appl Physiol (2014) 0.79
Inhibition of the aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity. J Endocrinol (2009) 0.79
The vitamin D receptor agonist BXL-01-0029 as a potential new pharmacological tool for the treatment of inflammatory myopathies. PLoS One (2013) 0.78
Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells. Steroids (2005) 0.78
Identification, characterization and biological activity of oxytocin receptor in the developing human penis. Mol Hum Reprod (2004) 0.78
The ontogenetic expression pattern of type 5 phosphodiesterase correlates with androgen receptor expression in rat corpora cavernosa. J Sex Med (2008) 0.77
Combined evaluation of resting IGF-I, N-terminal propeptide of type III procollagen (PIIINP) and C-terminal cross-linked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report. Clin Endocrinol (Oxf) (2004) 0.77
The phosphodiesterases type 5 inhibitor tadalafil reduces the activation of the hypothalamus-pituitary-adrenal axis in men during cycle ergometric exercise. Am J Physiol Endocrinol Metab (2012) 0.77
Levosimendan in critical illness: a literature review. J Clin Med Res (2014) 0.77
Cushing's syndrome in a patient with bilateral macronodular adrenal hyperplasia responding to cisapride: an in vivo and in vitro study. J Clin Endocrinol Metab (2003) 0.76
Effect of supra-physiological dose administration of rhGH on pituitary-thyroid axis in healthy male athletes. Regul Pept (2010) 0.75
Relationship between optimal lactate removal power output and Olympic triathlon performance. J Strength Cond Res (2007) 0.75
Feasibility and safety of minimal-incision thyroidectomy for Graves' disease: a prospective, single-center study. Head Neck (2012) 0.75
New therapeutical horizons in the management of postmenopausal osteoporosis. Aging Clin Exp Res (2013) 0.75
Commentaries on Viewpoint: A time for exercise: the exercise window. J Appl Physiol (1985) (2017) 0.75